UCB reports H1 profit rise

Published: 29 Jul 2011

UCB, the Belgian pharmaceutical company, has posted an 11 per cent increase in pre-tax profit to €443m for the first six months of 2011, reflecting a strong increase in sales.

The company's total revenue for the period increased by 2 per cent to €1.68bn. It reported significant sales growth of new medicines Cimzia (certolizumab pegol - 72 per cent), Vimpat (lacosamide - 76 per cent) and Neupro (rotigotine - 17 per cent). UCB also noted a strong performance of its anti-epileptic drug Keppra (levetiracetam) in Europe and Japan.

Roch Doliveux, CEO, said: "We are excited about the momentum of Cimzia, Vimpat and Neupro, about the potential UCB new medicines from our promising pipeline and about the fact that from 2012 onward, we will have a decade without impacts from major patent expiries."

The company's pipeline has been strengthened with positive phase III results for Cimzia in rheumatoid arthritis and Neupro for advanced Parkinson's disease.

Published: 29 Jul 2011

Comments are moderated and will not appear until approved by a member of the Communique team.